Roche to Continue Collaboration with EMA on Elevidys Therapy Following CHMP Negative Opinion

Source: Cailian Press

【Roche: To Continue Collaboration with EMA on Elevidys Therapy】According to财联社July 25, Roche announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion on the Conditional Marketing Authorization (CMA) application for Elevidys therapy for patients aged 3 to 7 with Duchenne Muscular Dystrophy (DMD). Roche stated that given the significant unmet medical needs in the DMD field, Roche plans to continue collaborating with the EMA to explore potential solutions.